Stock Events

Stock Events

Compass Pathways 

M$123.5
284
-M$4.57-3.57% Wednesday 18:45

Statistics

Day High
123.5
Day Low
123.5
52W High
128.07
52W Low
86.25
Volume
100
Avg. Volume
7,395
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-Profit Margin
Unprofitable
2022
2023
2024
0Revenue
-6.18BNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CMPSN.MX. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Mind Medicine Inc
MNMD
Mkt Cap1.38B
MindMed develops psychedelic-inspired medicines, directly competing in the psychedelic therapy space with Compass Pathways.
AtaiBeckley
ATAI
Mkt Cap1.56B
ATAI Life Sciences works on developing psychedelic and non-psychedelic compounds for mental health, a direct competitor in the psychedelic medicine field.
GH Research
GHRS
Mkt Cap888.26M
GH Research is focused on developing 5-MeO-DMT therapies for mental health disorders, competing in the same therapeutic area as Compass Pathways.
Cybin Inc
CYBN
Mkt Cap200.49M
Cybin Inc. is working on psychedelic drug development for mental health conditions, making it a competitor in the psychedelic-based treatment market.
Nuveen Municipal Income
NUMI
Mkt Cap0
Numinus Wellness focuses on psychedelic production and therapy, competing with Compass Pathways in the psychedelic mental health treatment market.
SPDR SSGA My2035 Corporate Bond
MYCO
Mkt Cap0
Mydecine Innovations Group is engaged in the development of psychedelic medicines, competing in the same space as Compass Pathways.
Revive Therapeutics
RVVTF
Mkt Cap4.68M
Revive Therapeutics is exploring the use of psychedelics for the treatment of mental illness and addiction, making it a competitor in the psychedelic therapy market.

About

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
Show more...
CEO
Mr. Kabir Kumar Nath M.A., M.B.A.
Employees
166
Country
GB
ISIN
US20451W1018

Listings

MX
MX
CMPSN.MX
F
DE
5Y6.F
XNAS
US
CMPS
BOATS
BOATS
CMPS.BOATS

0 Comments

Share your thoughts

FAQ

What is Compass Pathways stock price today?▼
The current price of CMPSN.MX is M$123.5 MXN — it has decreased by -3.57% in the past 24 hours. Watch Compass Pathways stock price performance more closely on the chart.
What is Compass Pathways stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Compass Pathways stocks are traded under the ticker CMPSN.MX.
What is Compass Pathways revenue for the last year?▼
Compass Pathways revenue for the last year amounts to 0 MXN.
What is Compass Pathways net income for the last year?▼
CMPSN.MX net income for the last year is -6.18B MXN.
How many employees does Compass Pathways have?▼
As of February 03, 2026, the company has 166 employees.
In which sector is Compass Pathways located?▼
Compass Pathways operates in the Health Care sector.
When did Compass Pathways complete a stock split?▼
Compass Pathways has not had any recent stock splits.
Where is Compass Pathways headquartered?▼
Compass Pathways is headquartered in London, GB.